AI
| Followers | 843 |
| Posts | 122806 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Tuesday, January 09, 2007 6:53:40 PM
My notes (from Oct 2006):
1. Hepsera (the black line on the chart) is the current market leader in Rx’s by a wide margin. This is bullish for IDIX because Tyzeka is a much more efficacious drug than Hepsera (#msg-14364568).
2. As new HBV drugs are launched, they expand the overall market rather than just stealing share from older drugs. This can be seen from the steady uptake of total prescriptions (the indigo line on the chart) during the period in which Baraclude and Hepsera were introduced. Despite being the oldest and least efficacious drug in the class, Epivir/Lamivudine (the red line on the chart) has maintained a near-constant number of prescriptions during the past four years.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
